SERA PROGNOSTICS, INC.

Print
General Information
Business:
We are a women’s health diagnostic company focused on improving pregnancy outcomes. Our first commercial product, the PreTRM test, is the only broadly validated commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. This test provides an accurate prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation. Anthem, Inc., whose health plans cover more than 10% of U.S. pregnancies annually, will make our PreTRM test available to eligible pregnant members during a multi-year contract. Anthem is the nation’s second-largest health insurer with more than 43 million members nationwide. 
 
(Note: Sera Prognostics priced its IPO on July 14, 2021, at $16 – the mid-point of its $15-to-$17 price range – on 4.69 million shares, the same number of shares in the prospectus, to raise $75.04 million.)
Industry: Services - Medical Laboratories
Employees: 76
Founded: 2008
Contact Information
Address 2749 East Parleys Way Suite 200 Salt Lake City, UT 84109
Phone Number (801) 990-0520
Web Address https://www.seraprognostics.com/​
View Prospectus: SERA PROGNOSTICS, INC.
Financial Information
Market Cap $488.16mil
Revenues $30.0 mil (last 12 months)
Net Income $-21.51 mil (last 12 months)
IPO Profile
Symbol SERA
Exchange NASDAQ
Shares (millions): 4.7
Price range $16.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Cowen and Company/ William Blair
CO-Managers -
Expected To Trade: 7/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change